Ceramedix

Ceramedix Holding, LLC is a privately held, preclinical-stage biotherapeutics company developing a new class of drugs aimed at addressing novel disease targets involving the microvasculature. Ceramedix technology utilizes patented intellectual property exclusively licensed from Memorial Sloan Kettering Cancer Center (MSK) to disrupt endothelial ceramide damage signaling, thereby restoring microvascular homeostasis. The company’s lead clinical indication is the treatment of severe microvascular system diseases associated with diabetes, with an initial focus on vascular diseases of the eye, particularly diabetic retinopathy. Other near-term opportunities include diabetic nephropathy and lung injury, including acute respiratory distress syndrome.